Vitamin D supplementation has been proven to have efficacy in thetreatment of allergic rhinitis (AR). We conducted the present study toexplore the role and efficacy of vitamin D adjuvant therapy in the inflammation in thepatients with AR. Methods: Out of the 127 patients with potential eligible AR, 60 wererandomly assigned into two groups and were finally included for analysis (n=30 foreach intervention). The patients with potential eligible AR were randomly allocated tointervention with desloratadine citrate disodium (DCD, 8.8 mg/day) without and withvitamin D3 nasal drops (1.5х106 IU, once/week) for four weeks. Thirty healthy controlsubjects were included in our study. We assessed the changes in the serum 25(OH)D,peripheral blood eosinophils, interleukin (IL)-4 levels, and nasal symptoms. Serum25(OH)D, peripheral blood eosinophils, and IL-4 levels were detected respectively withliquid chromatography-tandem mass spectrometry (LC-MS/MS), a blood detector, andenzyme-linked immunosorbent assay. Results: Our patients who received vitamin D3adjuvant therapy had a higher serum 25(OH)D level (47.57 ± 2.83 vs. 31.51 ± 2.95ng/ml) and lower AR symptoms score (2.07 ± 1.89 vs. 3.37 ± 1.50), serum IL-4 (10.38± 3.41 vs. 12.79 ± 5.40 pg/ml), and peripheral blood eosinophils (0.34 ± 0.09 vs. 0.41 ±0.10 109/l) compared with DCD single treatment. The effective rate of DCD with andwithout vitamin D3 in AR was 97% and 84%, respectively. Conclusion: Nasal vitaminD3 combined with DCD could improve the clinical symptoms of AR. Vitamin D3adjunct therapy showed impressive effects on inhibiting inflammation in patients withAR. We concluded that vitamin D3 supplementation into routine therapy could be aneffective adjuvant therapy in AR patients by inhibiting inflammation.
展开▼
